4th Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Labor-Health and Human Services Appropriations fiscal years 2010 and 2011. S. 3690, Drug Safety and Accountability Act of 2010, all provisions. H.R.6543, Drug Safety Enhancement Act of 2011. Contacts concerning Food and Drug Administration authority to manage drug shortages. Contacts concerning funding for section 3503 of H.R. 3590, Patient Protection and Affordable Care Act.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Drug Enforcement Administration (DEA); Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6543 (111th), H.R. 3590 (111th), S. 3690 (111th)

Medicare/Medicaid MMM

Communication with Centers for Medicare and Medicaid Services (CMS) regarding admnistration of medication to inpatients within 30 minutes of scheduled dosage time. Communication with CMS regarding Accountable Care Organizations and the Shared Savings Program.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Drug Enforcement Administration (DEA); Food & Drug Administration (FDA); Environmental Protection Agency (EPA)

Pharmacy PHA

H.R. 5389, The Medicare Clinical Pharmacist Practitioner Services Coverage Act of 2010, all provisions. Communications to Environmental Protection Agency on Draft Guidances for Best Management Practices for Unused Pharmaceuticals at Health Care Facilities; Pharmaceutical Waste. Communications to Food and Drug Administration (FDA) on Bar Code Label Requirements; Development and Distribution of Patient Medication Information for Prescription Drugs; and Generic Drug User Fees. Communications to FDA on Distribution of Medication Guide as part of Risk Evaluation and Mitigation Strategies; Approval Pathway for Biosimilars. Communication to Drug Enforcement Administration on Placement of Propofol into Schedule IV Controlled Substance.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —

Contacted: SENATE; Food & Drug Administration (FDA); Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5389 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.